ADVERTISEMENT

ESMO 2022 – Moving beyond chemotherapy in unfit lung cancer patients

Cristina Ferrario — Agenzia Zoe   |   Conference Report   |   12 September 2022
ADVERTISEMENT

Takeaway

  • First-line immunotherapy with atezolizumab led to significant survival benefits compared to chemotherapy in unfit patients with advanced/metastatic non-small-cell lung cancer (NSCLC) who were ineligible for platinum-based regimens.
  • Benefits were independent of PD-L1 status, performance status, and histology.
  • QoL was maintained and no new safety signals emerged.

Why this matters...

          

September Challenge

Ends in 4d 7h
left
right

Topic Challenges

left
right